Across TCGA pan-cancer cohorts, HMGN2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HMGN2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HMGN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HMGN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where HMGN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.700	0.957	.006	19	view →
PDAC	DFS	Tertile	III,IV	0.824	0.249	.007	9	view →
CCRCC	OS	Median	All	0.698	1.000	.007	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HMGN2 tumor-vs-normal RNA expression · all HMGN2 data types